Skip to main content

Table 1 Cell-line run controls

From: Nanoproteomic analysis of ischemia-dependent changes in signaling protein phosphorylation in colorectal normal and cancer tissue

Name

Origin

Treatment

Control

Provider

Jurkat

Human acute lymphocytic leukemia

200 nM PMA for 15 min

Positive for AKT, ERK1/2, and MEK1/2 phosphorylation

Indivumed GmbH

Jurkat

Human acute lymphocytic leukemia

1 µM staurosporine and 50 µM LY294002 for 2.5 h

Negative for AKT, ERK1/2, MEK1/2 phosphorylation

Indivumed GmbH

HT29

Human colon adenocarcinoma

Untreated

Positive for c-MET phosphorylation

Indivumed GmbH

HT29

Human colon adenocarcinoma

Calf intestinal alkaline phosphatase for 50 min

Negative for c-MET phosphorylation

Indivumed GmbH

  1. Compound-treated and compound-untreated cell lines have were as positive and negative controls for protein phosphorylation in order to control run quality. Compound treatment of cell lines is shown